Chemerin-9 (149-157)

Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism[1][2][3][4].

Product Specifications

CAS Number

[676367-27-4]

UNSPSC

12352209

Target

Akt; Amyloid-β; Chemerin Receptor; ERK; Reactive Oxygen Species (ROS)

Type

Peptides

Related Pathways

GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/chemerin-9-149-157.html

Solubility

H2O

Smiles

OC[C@@H](C(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@H](C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CCC(N)=O)NC(CNC([C@H]3N(C([C@H](CC4=CC=CC=C4)NC([C@H](CC5=CC=C(O)C=C5)N)=O)=O)CCC3)=O)=O)=O)=O)=O)=O

Molecular Formula

C54H66N10O13

Molecular Weight

1063.16

References & Citations

[1]Tu J, et, al. Regulatory effect of chemerin and therapeutic efficacy of chemerin 9 in pancreatogenic diabetes mellitus. Mol Med Rep. 2020 Mar;21 (3) :981-988.|[2]Chen S, et, al. Chemerin-9 Attenuates Experimental Abdominal Aortic Aneurysm Formation in ApoE-/- Mice. J Oncol. 2021 Apr 17;2021:6629204.|[3]Lei Z, et, al. Chemerin-9 Peptide Enhances Memory and Ameliorates Aβ1-42-Induced Object Memory Impairment in Mice. Biol Pharm Bull. 2020 Feb 1;43 (2) :272-283.|[4]Yamamoto A, et, al. Chemerin-9 stimulates migration in rat cardiac fibroblasts in vitro. Eur J Pharmacol. 2021 Dec 5;912:174566.

Shipping Conditions

Room temperature

Scientific Category

Peptides

Clinical Information

No Development Reported

Citation 01

Hypertension. 2024 Apr;81 (4) :861-875.|Eur J Neurosci. 2024 Sep;60 (5) :4830-4842.|Eur J Pharmacol. 2022 Dec 5:936:175343.|MedComm (2020) . 2024 Aug 31;5 (9) :e681.